MRKMerck Sharp & Dohme LLCSigning up patients
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Esophageal Squamous Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 298 (planned)
- Started
- Jul 30, 2025
- Main results expected
- Jan 4, 2032
- Fully finished
- Jan 4, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
Measured over: Up to approximately 28 days
Percentage of Participants who Experience an Adverse Event (AE)
Measured over: Up to approximately 77 months
Objective Response Rate (ORR)
Measured over: Up to approximately 77 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06780111 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC